(NASDAQ: NBIX) Neurocrine Biosciences's forecast annual revenue growth rate of 16% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.09%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Neurocrine Biosciences's revenue in 2024 is $1,887,100,000.On average, 11 Wall Street analysts forecast NBIX's revenue for 2024 to be $221,567,059,011, with the lowest NBIX revenue forecast at $215,911,351,802, and the highest NBIX revenue forecast at $230,956,884,290. On average, 11 Wall Street analysts forecast NBIX's revenue for 2025 to be $255,143,970,869, with the lowest NBIX revenue forecast at $237,802,999,602, and the highest NBIX revenue forecast at $292,751,035,580.
In 2026, NBIX is forecast to generate $294,288,525,808 in revenue, with the lowest revenue forecast at $261,565,388,214 and the highest revenue forecast at $357,928,441,530.